#Sweden #Stockholm #Orexo #AmorphOX #R&D Day

Orexo R&D Day: A Deep Dive into the Future

Orexo AB (Publ.), a prominent player in the pharmaceutical industry, is gearing up for its much-anticipated R&D Day scheduled for March 24, 2026. This event will take place at the prestigious Royal Swedish Academy of Engineering Sciences (IVA) located on Grev Turegatan 16, Stockholm, Sweden. It promises to be enlightening, drawing the attention of investors, analysts, and media alike.

The day's agenda showcases Orexo's commitment to innovation and strategic growth, particularly in light of recent organizational changes following the divestment of its product Zubsolv® in the US market. Notably, Orexo's cutting-edge delivery technology, AmorphOX®, will be a key focus, underscoring the company's dedication to enhancing drug delivery mechanisms across varying pharmaceutical applications.

Event Details and Key Presentations

Under the leadership of CEO Nikolaj Sørensen, attendees can expect a comprehensive overview of Orexo's updated strategies and research priorities. The day will commence at 9 am CET with registration and coffee, followed by a series of presentations that will cover:

• - Strategic Priorities: Nikolaj Sørensen will share insights into shaping Orexo's future, focusing on creating value and addressing current market needs.

• - AmorphOX® Technology Overview: Robert Rönn, SVP and Head of R&D, will outline how this proprietary technology transforms the delivery of biomolecules, making it easier and more convenient through nasal or tablet formats.

• - Product Development Updates: Detailed progress on innovative products like OX640, which aims to provide a reliable nasal epinephrine solution for severe allergy patients, and OX390, designed as a medical countermeasure against potent drug combinations linked to recent health crises, will be presented. These products are in response to emerging healthcare challenges concerning substances like xylazine and fentanyl.

The schedule includes a segment featuring expert analysis from Mark A. Smith, PhD, regarding why these countermeasures are necessary given the rising threat posed by specific drug combinations. His insights will emphasize the importance of proactive measures in healthcare and public safety.

Networking Opportunities

After a series of presentations, a question-and-answer session will allow the audience to engage directly with Orexo's management team. This inclusive segment will feature the opportunity for attendees to discuss the company's future trajectories and operational models, culminating in a networking lunch designed to foster connections and encourage collaborative insights within the industry.

This R&D Day reflects Orexo's broader mission: to innovate and respond effectively to severe diseases while ensuring that life-saving medications are developed to meet future healthcare demands. With over three decades of experience, Orexo continues to expand its pipeline and align with partners for research, development, and commercialization activities.

In summary, Orexo's R&D Day is not merely an event; it is a reflection of the company’s proactive approach to healthcare challenges, emphasizing strategy, innovation, and collaboration. For those interested in following Orexo's developments, updates will be available on their official website, and information about the event can be accessed through the dedicated R&D Day webpage.